Certification Record Filed in Class Action Commenced Against Diabetes Drug Manufacturers and Distributors: ACTOS Users Are at

Certification Record Filed in Class Action Commenced Against Diabetes Drug 
Manufacturers and Distributors: ACTOS Users Are at Heightened Risk of 
Developing Bladder Cancer 
TORONTO, Jan. 18, 2013 /CNW/ - On January 17, 2013, law firm Rochon Genova LLP 
filed its certification record in a proposed class action on behalf of users 
of a diabetes drug ACTOS (pioglitazone hydrochloride) against Takeda 
Pharmaceutical and Eli Lilly. The action alleges that the defendants knew or 
ought to have known that ACTOS materially increases the risks of bladder 
cancer and failed to disclose those risks in a timely manner and have failed 
to recall the drug in Canada. 
The case is brought by the daughter of a Toronto woman who died in April 2011 
after battling bladder cancer for more than two years following her use of 
ACTOS. Her daughter, a registered nurse, is confident in the strength of the 
evidence in support of the case: "I believe the expert evidence that's been 
filed confirms what manufacturers knew all along about the association 
between ACTOS and bladder cancer. They had this information and it should 
have been shared with doctors and patients years ago. There were much safer 
treatments my mother could have used to control her diabetes without putting 
her life at risk; she should have been given all the relevant information to 
make an informed choice about her treatment. That choice was taken away from 
her."The evidence in the record confirms the link between ACTOS and bladder 
cancer and includes the opinion of Dr. Bruce Trock, a Professor of 
Epidemiology at the Johns Hopkins University School of Medicine. Dr. Trock 
reviewed the relevant body of scientific literature and concluded that "…the 
body of evidence from epidemiologic studies of pioglitazone [ACTOS] and 
bladder cancer supports the conclusion that pioglitazone is a risk factor for 
bladder cancer". 
The record also contains the report of Dr. Michael Pollak, a Professor of 
Oncology at McGill's Faculty of Medicine. Dr. Pollak noted the early 
evidence for the association between ACTOS and bladder cancer in preclinical 
toxicity studies. In his view, given the availability of safe alternative 
therapies, such as metformin, and the very significant morbidity and mortality 
associated with bladder cancer, all knowledge of a potential association 
between ACTOS and the development of bladder cancer should have been disclosed 
by the manufacturers in the information used by prescribing physicians. 
A third report by consultants at AxSource, a Canadian regulatory consulting 
firm, concluded that the information about ACTOS published in the desk 
reference used by Canadian physicians did not accurately reflect the knowledge 
of the manufacturers about the drug's association with bladder cancer. 
The allegations raised in the claim have not yet been proven in court. The 
plaintiff and class members are represented by the Toronto based law firm of 
Rochon Genova LLP. 
Rochon Genova LLP 121 Richmond St. W, Suite 900 Toronto, Ontario M5H 2K1 
Telephone: (416) 363-1867 or toll-free: 1-866-881-2292 Website 
To view this news release in HTML formatting, please use the following URL: 
ST: Ontario
-0- Jan/18/2013 12:30 GMT
Press spacebar to pause and continue. Press esc to stop.